MDGLMadrigal Pharmaceuticals, Inc.

MDGL Stock Price, Valuation & Chart | Madrigal Pharmaceuticals, Inc.

Compare

$538.71-1.32 (-0.24%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology MDGL intrinsic value MDGL calculated fair value vs price

Overview Financials Dividends Ratios

MDGL Historical price chart

MDGL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization12.45B

PE Ratio-42.09

EPS-12.8

Trading Volume165.74K

Today's High/Low540.75/533.26

Dividend Yield0.00

52 Week High/Low615.0/393.61

Shares Outstanding23.10M

MDGL Financial Statement

MDGL Analyst ratings

MDGL Analysis & performance metrics

MDGL Company profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of…

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of…

MDGL Management team

Name

Position

Tina E. Ventura

Chief Investor Relations Officer

Mark Underwood

Executive Vice President of Business Planning & Operations

Mardi C. DierCFO

Executive Vice President & Chief Financial Officer

Shannon Kelley

Executive Vice President, Chief Legal Officer & Corporate Secretary

Carole Huntsman

Executive Vice President & Chief Commercial Officer

Clint Wallace

Executive Vice President & Chief Human Resources Officer

Ronald FilippoCTO

Executive Vice President & Chief Information Officer

Rebecca A. Taub M.D.CTO

Founder, Senior Scientific & Medical Advisor and Director

Name

Position

Tina E. Ventura

Chief Investor Relations Officer

Mark Underwood

Executive Vice President of Business Planning & Operations

Mardi C. DierCFO

Executive Vice President & Chief Financial Officer

Shannon Kelley

Executive Vice President, Chief Legal Officer & Corporate Secretary

Carole Huntsman

Executive Vice President & Chief Commercial Officer

Clint Wallace

Executive Vice President & Chief Human Resources Officer

Ronald FilippoCTO

Executive Vice President & Chief Information Officer

Rebecca A. Taub M.D.CTO

Founder, Senior Scientific & Medical Advisor and Director

Management Team

Tina E. Ventura

Chief Investor Relations Officer

Mark Underwood

Executive Vice President of Business Planning & Operations

Mardi C. DierCFO

Executive Vice President & Chief Financial Officer

Shannon Kelley

Executive Vice President, Chief Legal Officer & Corporate Secretary

Carole Huntsman

Executive Vice President & Chief Commercial Officer

Clint Wallace

Executive Vice President & Chief Human Resources Officer

Ronald FilippoCTO

Executive Vice President & Chief Information Officer

Rebecca A. Taub M.D.CTO

Founder, Senior Scientific & Medical Advisor and Director

Management

Tina E. Ventura

Chief Investor Relations Officer

Mark Underwood

Executive Vice President of Business Planning & Operations

Mardi C. DierCFO

Executive Vice President & Chief Financial Officer

Shannon Kelley

Executive Vice President, Chief Legal Officer & Corporate Secretary

Carole Huntsman

Executive Vice President & Chief Commercial Officer

Clint Wallace

Executive Vice President & Chief Human Resources Officer

Ronald FilippoCTO

Executive Vice President & Chief Information Officer

Rebecca A. Taub M.D.CTO

Founder, Senior Scientific & Medical Advisor and Director

Total 8 executives

MDGL Frequently asked questions

What is Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price?

Current stock price of Madrigal Pharmaceuticals, Inc. (MDGL) stock is $538.71. The stock price is -0.24% lower in the session. The intraday range can be seen from this page. Volume of Madrigal Pharmaceuticals, Inc. (MDGL) stock is 165.74K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Madrigal Pharmaceuticals, Inc. (MDGL) stock price going up or down today?

The stock price of Madrigal Pharmaceuticals, Inc. (MDGL) can change with earnings, company news, and overall market sentiment. Madrigal Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Madrigal Pharmaceuticals, Inc. stock expensive at its current price?

Whether Madrigal Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for MDGL on this page is -42.09. EPS on this page is -12.80. Compare those figures with peers and growth expectations before deciding if the current Madrigal Pharmaceuticals, Inc. price is justified.

How has the stock price of Madrigal Pharmaceuticals, Inc. (MDGL) performed historically?

Historical performance for Madrigal Pharmaceuticals, Inc. (MDGL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how MDGL reacted to past earnings and market events.

Should I buy Madrigal Pharmaceuticals, Inc. (MDGL) stock, at this price?

Buying Madrigal Pharmaceuticals, Inc. (MDGL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.